Shared Decision Making for PFO Closure: How to Make the FDA Requirements Work (and, are they requirements?)

Megan Coylewright, MD MPH Associate Director, Structural Heart Disease Dartmouth-Hitchcock Heart and Vascular Center The Dartmouth Institute





## **Disclosure Statement of Financial Interest**

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

### **Affiliation/Financial Relationship**

- Grant/Research Support
- Consulting Fees/Honoraria
- Major Stock Shareholder/Equity
- Royalty Income
- Ownership/Founder
- Intellectual Property Rights
- Other Financial Benefit

### Company

- None
- Boston Scientific, Edwards Lifesciences
- None
- None
- None
- None
- None





### Agenda

- FDA mandates age, neurology and cardiology assessment of stroke etiology, and device
- Recommendation for shared decision making in IFU
- Controversial: is PFO closure in cryptogenic stroke a preference-sensitive decision?





Re: P120021

Trade/Device Name: AMPLATZER PFO Occluder
Filed: November 30, 2012
Amended: August 12, 2013, September 9, 2013, February 26, 2014, April 28, 2014, July 1, 2014, February 27, 2015, September 17, 2015, October 8, 2015
Product Code: MLV

Dear Rashmi Bhushan:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) for the AMPLATZER PFO Occluder. This device is indicated for percutaneous transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke. We are pleased to inform you that the PMA is approved. You may begin commercial distribution of the device in accordance with the conditions of approval described below.

# AMPLATZER<sup>™</sup> PFO Occluder



#### **Device Description**

The AMPLATZER<sup>™</sup> PFO Occluder (Figure 1) is a self-expandable, double-disc device made from a Nitir discs are linked together by a short connecting waist. In order to increase its closing ability, the discs c fabric. The polyester fabric is securely sewn to each disc by a polyester thread.

The device has radiopaque marker bands on the distal and proximal ends of the device. The device cont the proximal end to facilitate delivery and deployment. The device is sterilized with ethylene oxide.

## **Amplatzer PFO Occluder IFU**

#### **Patient Selection for Treatment**

In considering effectiveness o decision-makin AMPLATZER™ additional infor

It is recommended process where the taking into accour ..recommended that the medical team (neurologist and cardiologist) and the patient engage in a shared decisionmaking process...taking into account the patient's values and preferences I the safety and A shared the use of the +s" sections for

cision-making discussed while Patient Guide and

in the Clinical Studies section of the instructions for Use.





### **FDA requirements for PFO closure**

Ages 18-60 years

 Cryptogenic stroke determined by neurologist and cardiologist

Amplatzer PFO Occluder device





### Shared decision making in PFO closure

- "(I)t is essential that we engage in shared decision making with neurologists..."
- "Team-based, multidisciplinary, Bayesian clinical judgment on an individual basis still remains the core of decision-making."
- "(T)he medical team and the patient (discuss) risks and benefits...while taking into account the patient's values and preferences."


Poulin and Kavinsky. Cardiac Interventions Today. May/June 2017; Pristipino et al. Catheterization and Cardiovascular Interventions 2013; Instructions for Use, Amplatzer PFO Occluder



## **Common myths**

- The decision is shared between the two subspecialists- and a recommendation is made
- Impossible- patients always ask me what I would do
- We already do it perfectly (or, at least, our patients are happy)
- It's easy! Just give the patient a pamphlet to review

Legare, Thompson-Leduc. Patient Educ Couns 2014



## **Patient materials- 8 pages**

### Patent Foramen Ovale Closure with the AMPLATZER™ PFO Occluder

#### Information Guide for Patients and Caregivers

This guide is for patients who have previously suffered a stroke that was from an unknown cause (also called "cryptogenic stroke") and also have an opening between the two upper chambers of the heart that never fully closed after birth. The medical term for this opening in the heart is a patent foramen ovale (PFO). The information in this patient guide will help you learn more about cryptogenic stroke, PFO, and treatments to reduce the chance of having another stroke. Be sure to ask your physician to explain all of your treatment options and risks and benefits of each.





#### Review

Knowledge is *not* power for patients: A systematic review and thematic synthesis of patient-reported barriers and facilitators to shared decision making




Natalie Joseph-Williams<sup>a,\*</sup>, Glyn Elwyn<sup>b</sup>, Adrian Edwards<sup>a</sup>

<sup>a</sup> Cochrane Institute of Primary Care and Public Health, Cardiff University, Cardiff, UK
<sup>b</sup> The Dartmouth Center for Health Care Delivery Science, Dartmouth College, Hanover, USA

#### ARTICLE INFO

Article history: Received 8 August 2013 Received in revised form 16 October 2013 Accepted 30 October 2013

Keywords: Shared decision making Implementation Patient-reported barriers/facilitators Patient-centered healthcare






Joseph-Williams, Edwards, et al. Patient Educ Couns 2014

## "At one year from now, what are the things that are most important?"













### Who mandates a shared decision making approach?







### **Preference-sensitive decisions**

- More than one reasonable option exists
- Uncertainty exists in evidence
- Patient preferences vary (i.e. geographically) or are distinct from healthcare professional preferences






### **CMS** defines preference-sensitive conditions

• "(A) medical condition in which the clinical evidence does not clearly support one treatment option, and the appropriate course of treatment depends on the values or preferences of the beneficiary regarding... the scientific evidence for each treatment option."






## Medicare National Coverage Decision for left atrial appendage closure



least 12 are LAAC, over a two year period.







## **Product labeling: patient handout**

#### Rate 50% less strokes with the device compared poin rate thing to medication unde

of the RESPECT Trial were analyzed at two time e follow-up was about 3 years, showed that the vith the AMPLATZER<sup>™</sup> PFO Occluder plus bloodcation alone. However, it is important to ither treatment group. The analysis suggested

that if 1000 patients were treated with PEO closure, about 6 of these patients would have a stoke after 1 year compared with about 12 o

The second analysis, performed w patients were treated with PFO clo compared with about 10 out of 1

# Of 1000 people, there were 6 less strokes with the device compared to medication





### Conclusion

- FDA mandates age, neurology and cardiology assessment of stroke etiology, and device
- Recommendation for shared decision making in IFU
- Controversial: is PFO closure in cryptogenic stroke a preference-sensitive decision?



